HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer

Singh, Mantosh Kumar; Pindiprolu, Sai Kiran S. S.; Sanapalli, Bharat Kumar Reddy; Yele, Vidyasrilekha; Ganesh, G. N. K.

doi:10.1016/j.ijbiomac.2020.02.131

Cited by 16 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, CTHP-CAP-LPs caused notable cytotoxicity in comparison to the non-targeted formulation because of the former’s higher specificity and cellular absorption in cancer cells overexpressing the HER2 gene. 69 Ghassami et al proposed a nano formulation consisting of polymeric NPs loading docetaxel and functionalized by aptamer to target HER2 to treat ovarian cancer. This formula minimized the off-target side effects and provided a higher drug concentration in tumor cells.…”

Section: Intrinsic-activationmentioning

confidence: 99%

“…-NPs conjugated to ligands that is targeted to bind molecules found in tumor cells in higher concentration than in normal cells Tf, TfR, 60,61 EGFR, 62,63 PSMA, 64,65 FR, 66,67 HER2, 69,70 ER, 71 CD-44, 72,73 Integrin, 74,75 Biotin receptor, 76 LHRH receptor, 77 lectin 78,79 , GSH [80][81][82] Ultrasound activation -mRNA-lipoplexes bound to microbubbles 123 -Nanobubbles composed of NPs enclosing gas is stabilized within a single cavity of nano-cups or nano-cone 124 -Nanosized lipid droplets 125 -Barium titanate as a piezoelectric NP 129 Magnetic field activation -Biodegradable dendritic silica NPs encapsulating glucose oxidase and Fe 3 O 4 NPs 141 -Anticancer drugs conjugated with magnetic NPs 142,143,145 -Magnetite particles used as a pore blocking 150 -Cationic lipopeptides and anionic magnetic NPs system in magnetofection 153,155 Light activation/Photodynamic therapy -Near infrared 161,162 -Visible light 163,164 -X-ray 165 (Continued) https://doi.org/10.2147/IJN.S386037…”

Section: Concentration Dependent Activationmentioning

confidence: 99%

See 1 more Smart Citation

Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques

Hamdy¹,

Eskander²,

Basalious³

2022

IJN

View full text Add to dashboard Cite

Anti-cancer conventional chemotherapeutic drugs novel formula progress, nowadays, uses nano technology for targeted drug delivery, specifically tailored to overcome therapeutic agents’ delivery challenges. Polymer drug delivery systems (DDS) play a crucial role in minimizing off-target side effects arising when using standard cytotoxic drugs. Using nano-formula for targeted localized action, permits using larger effective cytotoxic doses on a single special spot, that can seriously cause harm if it was administered systemically. Therefore, various nanoparticles (NPs) specifically have attached groups for targeting capabilities, not seen in bulk materials, which then need activation. In this review, we will present a simple innovative, illustrative, in a cartoon-way, enumeration of NP anti-cancer drug targeting delivery system activation-types. Area(s) covered in this review are the mechanisms of various NP activation techniques.

show abstract

Section: Intrinsic-activationmentioning

confidence: 99%

Section: Concentration Dependent Activationmentioning

confidence: 99%

Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques

Hamdy¹,

Eskander²,

Basalious³

2022

IJN

View full text Add to dashboard Cite

show abstract

“…In a recent study, Kumar Singh et al explored the effectiveness of a HER2 receptortargeting peptide by conjugating it with chitosan-modified liposome with loaded capecitabine (CAP) [114]. The surface of the CAP-loaded liposome was modified with chitosan and tumor homing peptide (THP) for selective targeting of the HER2 receptor of breast cancer cells to minimize the off-target effects of conventional CAP.…”

Section: Her-2 Targeted Drug-loaded Npsmentioning

confidence: 99%

“…In a mouse breast tumor model (created by injecting 1 × 10 7 MCF-7 cells), CTHP-CAP-LPs showed superior antitumor effects with 96% reduction of the tumor volume and extended mouse survival compared to the non-targeted CAP formulation. The dose of CAP used was 20 mg/kg of the mouse body weight [114].…”

Section: Her-2 Targeted Drug-loaded Npsmentioning

confidence: 99%

Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

2021

View full text Add to dashboard Cite

The journey of chemotherapeutic drugs from the site of administration to the site of action is confronted by several factors including low bioavailability, uneven distribution in major organs, limited accessibility of drug molecules to the distant tumor tissues, and lower therapeutic indexes. These unavoidable features of classical chemotherapeutics necessitate an additional high, repetitive dose of drugs to obtain maximum therapeutic responses with the result of unintended adverse side effects. An erratic tumor microenvironment, notable drawbacks of conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells warrant precisely designed therapeutics for the treatment of cancers. In recent decades, nanoparticles have been deployed for the delivery of standard anticancer drugs to maximize the therapeutic potency while minimizing the adverse effects to increase the quality and span of life. Several organic and inorganic nanoplatforms that have been designed exploiting the distinctive features of the tumor microenvironment and tumor cells offer favorable physicochemical properties and pharmacokinetic profiles of a parent drug, with delivery of higher amounts of the drug to the pathological site and its controlled release, thereby improving the balance between its efficacy and toxicity. Advances to this front have included design and construction of targeted nanoparticles by conjugating homing devices like peptide, ligand, and Fab on the surface of nanomaterials to navigate nanoparticledrug complexes towards the target tumor cell with minimal destruction of healthy cells. Furthermore, actively targeting nanoparticles can facilitate the delivery and cellular uptake of nanoparticle-loaded drug constructs via binding with specific receptors expressed aberrantly on the surface of a tumor cell. Herein, we present an overview of the principle of targeted delivery approaches, exploiting drug-nanoparticle conjugates with multiple targeting moieties to target specific receptors of breast cancer cells and highlighting therapeutic evaluation in preclinical studies. We conclude that an understanding of the translational gap and challenges would show the possible future directions to foster the development of novel targeted nanotherapeutics.

show abstract

“…In a similar manner, Mobaserri et al [95], with the aim of improving lapatinib solubility and bioavailability, encapsulated it in dextran-chitosan NPs that were also demonstrated to have an anti-HER2+ cell growth activity. On the other hand and regarding liposomes, Singh et al synthesized chitosan-modified liposomes and decorated them with an anti-HER2 tumor homing peptide (THP) (WNLPWYYSVSPTC) to specifically transport the pro-drug capecitabine to HER2+ breast cancer cells [96]. Otherwise, MM-302 is an HER2-targeted liposome encapsulating doxorubicin in its core, with single chain anti-HER2 antibodies (scFv) conjugated to its surface.…”

Section: Current and Future Situation Of Trastuzumab-based Nanomedicinementioning

confidence: 99%

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

2020

View full text Add to dashboard Cite

HER2 overexpression, which occurs in a fifth of diagnosed breast cancers as well as in other types of solid tumors, has been traditionally linked to greater aggressiveness. Nevertheless, the clinical introduction of trastuzumab has helped to improve HER2-positive patients’ outcomes. As a consequence, nanotechnology has taken advantage of the beneficial effects of the administration of this antibody and has employed it to develop HER2-targeting nanomedicines with promising therapeutic activity and limited toxicity. In this review, the molecular pathways that could be responsible for trastuzumab antitumor activity will be briefly summarized. In addition, since the conjugation strategies that are followed to develop targeting nanomedicines are essential to maintaining their efficacy and tolerability, the ones most employed to decorate drug-loaded nanoparticles and liposomes with trastuzumab will be discussed here. Thus, the advantages and disadvantages of performing this trastuzumab conjugation through adsorption or covalent bindings (through carbodiimide, maleimide, and click-chemistry) will be described, and several examples of targeting nanovehicles developed following these strategies will be commented on. Moreover, conjugation methods employed to synthesized trastuzumab-based antibody drug conjugates (ADCs), among which T-DM1 is well known, will be also examined. Finally, although trastuzumab-decorated nanoparticles and liposomes and trastuzumab-based ADCs have proven to have better selectivity and efficacy than loaded drugs, trastuzumab administration is sometimes related to side toxicities and the apparition of resistances. For this reason also, this review focuses at last on the important role that newer antibodies and peptides are acquiring these days in the development of HER2-targeting nanomedicines.

show abstract

HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer

Cited by 16 publications

References 18 publications

Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques

Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques

Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

Contact Info

Product

Resources

About